

Counts
6000
4000
2000
0
10
20
30
40
Position [°2Theta] (1.54060[A])
Compound 1 Form A
Compound 1 Form B
Compound 1 Form C
Compound 1 Form D
Compound 1 Form E

FIG. 1



Counts
Compound 1 Form A
2000
1000
0
10
20
30
40
Position [°2Theta] (1.54060[A])

FIG. 2



TGA
Size: 4.1090 mg
Run Date: 12-Mar-2010 11:00
Instrument: TGA Q5000 V3.10 Build 258
0.008850%
(0.0003637mg)
Weight (%)
Deriv. Weight Change(%/°C)
Temperature (°C)
Universal V4.5A TA Instruments
101
100
99
98
97
0.10
0.08
0.06
0.04
0.02
0.00
-0.02
0
50
100
150
200
250
300

FIG. 3



Size: 2.3730 x 0.0000 mg
Method: Ramp
DSC
Run Date: 12-Mar-2010 10:58
Instrument: DSC Q2000 V24.4 Build 116
268.42°C
135.4 J/g
269.62°C
Heat Flow (W/g)
Exo Up
Temperature (°C)
Universal V4.5A TA Instruments
2
0
-2
-4
-6
-8
-10
0
50
100
150
200
250
300

FIG. 4



Compound 1 Form A
DVS Isotherm Plot
Temp: 24.7°C
Meth: 0-95 dm-dt 0.001.SAO
M(0): 8.2341
Cycle 1 Sorp
Cycle 1 Desorp
Change In Mass(%)-Dry
0.5
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
0
10
20
30
40
50
60
70
80
90
100
TargetRH(%)

FIG. 5



Counts
Compound 1 Form A 2000psi
2000
1000
0
10
20
30
40
Position [°2Theta] (1.54060[A])

FIG. 6



Counts
800
600
400
200
0
Compound 1 Form B
10
20
30
40
Position [°2Theta] (1.54060[A])

FIG. 7



Size: 6.1060 mg
TGA
Run Date: 29-Mar-2010 10:26
Comment: Batch#7541-096-G
Instrument: TGA Q5000 v3.10 Build 258
102
100
98
96
94
92
90
88
Weight (%)
0.3
0.2
0.1
0.0
-0.1
Deriv. Weight Change(%/°C)
9.479%
(0.5703mg)
0
50
100
150
200
250
300
Temperature (°C)
Universal V4.5A TA Instruments

FIG. 8



Size: 0.0000 x 0.0000 mg
Method: Ramp
DSC
Run Date: 24-Mar-2010 14:07
Instrument: DSC Q2000 V24.4 Build 116
143.51°C
1.011mW
158.80°C
1.293mW
264.99°C
101.7mJ
133.79°C
0.4023mW
98.36°C
-0.4624mW
267.76°C
Heat Flow (mW)
Exo Up
Temperature (°C)
Universal V4.5A TA Instruments

FIG. 9



5831-28A_010001r.esp
0.61 0.25
0.08
0.03
0.25 3.48 0.77
1.74 9.81 14.77 3.00 1.45
Chemical Shift (ppm)

FIG. 10



Compound 1 Form B
DVS Isotherm Plot
Temp: 23.8 °C
Meth: 50-90-0-50.SAO
M(0): 5.3124
Cycle 1 Sorp
Cycle 1 Desorp
Cycle 2 Sorp
Change In Mass(%)-Dry
TargetRH(%)
0
5
10
15
20
25
0
10
20
30
40
50
60
70
80
90
100

FIG. 11



Counts
Compound 1 Form C
2000
1000
0
10
20
30
40
Position [°2Theta] (1.54060[A])

FIG. 12



Size: 4.3060 mg
Comment: Batch#7541-096-G
TGA
Run Date: 29-Mar-2010 11:48
Instrument: TGA Q5000 v3.10 Build 258
Weight (%)
Deriv. Weight Change(%/°C)
9.821%
(0.4229mg)
Temperature (°C)
Universal V4.5A TA Instruments

FIG. 13



Size: 0.0000 x 0.0000 mg
Method: Ramp
DSC
Run Date: 24-Mar-2010 15:15
Instrument: DSC Q2000 V24.4 Build 116
135.87°C
2.226mW
268.65°C
299.2mJ
122.68°C
-1.735mW
95.58°C
-2.886mW
270.28°C
Heat Flow (mW)
Exo Up
Temperature (°C)
Universal V4.5A TA Instruments

FIG. 14



5831-28-C_010001r
0.63
0.25
3.51
0.91
1.84
12.37
18.81
2.99
1.74
Chemical Shift (ppm)

FIG. 15



Compound 1 Form C
DVS Isotherm Plot
Temp: 23.7°C
Meth: 50-90-0-50.SAO
M(0): 2.4061
Cycle 1 Sorp
Cycle 1 Desorp
Cycle 2 Sorp
Change In Mass(%)-Dry
TargetRH(%)
0
2
4
6
8
10
12
14
0
10
20
30
40
50
60
70
80
90
100

FIG. 16



Counts
Compound 1 Form D
800
600
400
200
0
10
20
30
40
Position [°2Theta] (1.54060[A])

FIG. 17



Size: 7.3820 mg
Comment: Batch#7541-096-G
TGA
Run Date: 29-Mar-2010 13:10
Instrument: TGA Q5000 V3.10 Build 258
18.57%
(1.371mg)
Weight (%)
Deriv. Weight Change(%/°C)
Temperature (°C)
Universal V4.5A TA Instruments

FIG. 18



Size: 0.0000 x 0.0000 mg
Method: Ramp
Comment: Batch 7541-096-G
DSC
Run Date: 24-Mar-2010 10:42
Instrument: DSC Q2000 V24.4 Build 116
140.79°C
58.94mJ
268.27°C
238.0mJ
141.37°C
269.04°C
Heat Flow (mW)
Exo Up
Temperature (°C)
Universal V4.5A TA Instruments

FIG. 19



5831-34-A_020001r.esp
0.74 0.17 0.22 17.58 1.02 2.01 9.04 13.73 6.16 3.00 2.98
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)

FIG. 20



Counts
2000
1000
0
Compound 1 Form E
10
20
30
40
Position [°2Theta] (1.54060[A])

FIG. 21



Size: 3.0990 mg
TGA
Run Date: 21-Jul-2010 15:03
Instrument: TGA Q5000 V3.10 Build 258
3.143%
(0.09739mg)
2.097%
(0.06500mg)
Weight (%)
Deriv. Weight Change(%/°C)
Temperature (°C)
Universal V4.5A TA Instruments

FIG. 22



DSC
Operator: Jean Xu
Run Date: 21-Jul-2010 11:22
Instrument: DSC Q2000 V24.4 Build 116
Size: 0.0000 mg
Method: Ramp
180.39°C
268.34°C
247.0mJ
175.34°C
37.91mJ
269.68°C
Heat Flow (mW)
Exo Up
Temperature (°C)
Universal V4.5A TA Instruments

FIG. 23



1.155
1.178
1.201
2.491
2.497
2.503
2.509
2.515
2.670
2.729
3.323
4.014
4.037
4.060
4.083
4.215
7.713
7.900
7.931
7.962
7.989
8.011
8.038
8.078
8.668
14.609
ppm
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
3.607
8.875
2.950
3.607
1.966
2.000
0.043
0.938
3.602
0.326
0.656
0.264

FIG. 24





Compound 1 Form E
DVS Isotherm Plot
Temp: 24.0°C
Meth: 0-95 dm-dt 0.001.SAO
M(0): 3.7233
Cycle 1 Sorp
Cycle 1 Desorp
Change In Mass(%)-Dry
TargetRH(%)
7
6
5
4
3
2
1
0
-1
0
10
20
30
40
50
60
70
80
90
100

FIG. 25



(70% major tautomer)



(30% minor tautomer)

FIG. 26



21
22
25
23
2.23
2.08
2.09
0.77
3.00
4.6 4.4 4.2 4.0 3.8 3.6 3.4 3.2 3.0 2.8 2.6 2.4 2.2 2.0 1.8 1.6 1.4 1.2 1.0
f1(ppm)

FIG. 27




FIG. 27 (Continued)




FIG. 27 (Continued)



21
22
25
23
2.23
2.08
2.09
0.77
3.00
4.6 4.4 4.2 4.0 3.8 3.6 3.4 3.2 3.0 2.8 2.6 2.4 2.2 2.0 1.8 1.6 1.4 1.2 1.0
f1(ppm)

FIG. 28




FIG. 28 (Continued)




FIG. 28 (Continued)



20
15
11
5
3
17
6
12
13
9
10
7
166 164 162 160 158 156 154 152 150 148 146 144 142 140 138 136 134 132 130 128 126 124 122 120 118
f1(ppm)

FIG. 29




FIG. 29 (Continued)



20
5
11
6
3
17
12
9
13
15
10
7
166 164 162 160 158 156 154 152 150 148 146 144 142 140 138 136 134 132 130 128 126 124 122 120 118
f1(ppm)

FIG. 30




FIG. 30 (Continued)



Dissolution Averages For Formulation 1, Low Strength (1 mg)
Percent Released
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
20
40
60
80
100
Time (min)
Form 1, Low, 0
Form 1, Low, 6
Dissolution Averages For Formulation 5, Low Strength (1 mg)
Percent Released
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
20
40
60
80
100
Time (min)
Form 5, Low, 0
Form 5, Low, 6

FIG. 31




FIG. 31 (Continued)



Dissolution Averages For Formulation 1, High Strength (25 mg)
110%
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Percent Released
0
20
40
60
80
100
Time (Min)
Form 1 T=0
Form 1 T=4
Dissolution Averages For Formulation 5, High Strength (25 mg)
110%
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Percent Released
0
20
40
60
80
100
Time (Min)
Form 5 T=0
Form 5 T=4

FIG. 32




FIG. 32 (Continued)



Screening Period
Day -28 to substudy Day 1
Bioavailability Substudy*
Treatment 1 (AIC, fasted)
Treatment 2 (tablet, fasted)
Treatment 3 (tablet, fed)
Treatment & Evaluation
28-day (BID) cycles until tumor progression, unacceptable toxicity or subject/physician decision to discontinue Comp. 1.
End of Treatment & Follow-up
End of treatment procedures within 21 days of last dose.
Follow-up for 28 days after last dose for final safety assessment.

FIG. 33